Escalon Medical Corp.: 10-Q filed 2018-02-14
What Escalon Medical Corp. reported in its quarterly report filed 2018-02-14 (fiscal Q2 2018): 32 published measures, 88 facts as tagged in accession 0000862668-18-000004.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2018-02-14
- Fiscal period
- fiscal Q2 2018
- Accession
- 0000862668-18-000004 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Escalon Medical Corp. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 5,798,765 | USD | |
| At 2017-06-30 | 4,984,170 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 3,964,486 | USD | |
| At 2017-06-30 | 3,800,590 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 1,834,279 | USD | |
| At 2017-06-30 | 1,183,580 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 788,211 | USD | |
| At 2017-06-30 | 544,118 | USD | |
| At 2016-12-31 | 538,284 | USD | |
| At 2016-06-30 | 538,114 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | 711,220 | USD | 92 |
| 2017-07-01 to 2017-12-31 | 650,699 | USD | 184 |
| 2016-10-01 to 2016-12-31 | -64,957 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -460,489 | USD | 184 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-12-31 | -281,201 | USD | 184 |
| 2016-07-01 to 2016-12-31 | -516,830 | USD | 184 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-12-31 | 40,000 | USD | 184 |
| 2016-07-01 to 2016-12-31 | 517,000 | USD | 184 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-12-31 | 485,294 | USD | 184 |
| 2016-07-01 to 2016-12-31 | 0 | USD | 184 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | -67,875,179 | USD | |
| At 2017-06-30 | -68,525,878 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | 7,551,430 | shares | 92 |
| 2017-07-01 to 2017-12-31 | 7,551,430 | shares | 184 |
| 2016-10-01 to 2016-12-31 | 7,551,430 | shares | 92 |
| 2016-07-01 to 2016-12-31 | 7,551,430 | shares | 184 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | 7,551,430 | shares | 92 |
| 2017-07-01 to 2017-12-31 | 7,551,430 | shares | 184 |
| 2016-10-01 to 2016-12-31 | 7,551,430 | shares | 92 |
| 2016-07-01 to 2016-12-31 | 7,551,430 | shares | 184 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | 0.09 | USD/shares | 92 |
| 2017-07-01 to 2017-12-31 | 0.09 | USD/shares | 184 |
| 2016-10-01 to 2016-12-31 | -0.01 | USD/shares | 92 |
| 2016-07-01 to 2016-12-31 | -0.06 | USD/shares | 184 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | 0.09 | USD/shares | 92 |
| 2017-07-01 to 2017-12-31 | 0.09 | USD/shares | 184 |
| 2016-10-01 to 2016-12-31 | -0.01 | USD/shares | 92 |
| 2016-07-01 to 2016-12-31 | -0.06 | USD/shares | 184 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 43,931 | USD | |
| At 2017-06-30 | 54,892 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | 245,137 | USD | 92 |
| 2017-07-01 to 2017-12-31 | 217,865 | USD | 184 |
| 2016-10-01 to 2016-12-31 | -42,510 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -427,788 | USD | 184 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 4,978,653 | USD | |
| At 2017-06-30 | 4,155,372 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | 34,562 | USD | 92 |
| 2017-07-01 to 2017-12-31 | 68,010 | USD | 184 |
| 2016-10-01 to 2016-12-31 | 22,489 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 32,802 | USD | 184 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 3,199,229 | USD | |
| At 2017-06-30 | 3,001,243 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 945,327 | USD | |
| At 2017-06-30 | 1,047,463 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 0 | USD | |
| At 2017-06-30 | 400 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 1,926,078 | USD | |
| At 2017-06-30 | 1,483,770 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 2,067,414 | USD | |
| At 2017-06-30 | 1,917,938 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | 1,192,624 | USD | 92 |
| 2017-07-01 to 2017-12-31 | 2,189,129 | USD | 184 |
| 2016-10-01 to 2016-12-31 | 1,206,888 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 2,362,303 | USD | 184 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | 107,509 | USD | 92 |
| 2017-07-01 to 2017-12-31 | 300,590 | USD | 184 |
| 2016-10-01 to 2016-12-31 | 286,135 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 596,494 | USD | 184 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 7,526,430 | shares | |
| At 2017-06-30 | 7,526,430 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 69,701,907 | USD | |
| At 2017-06-30 | 69,701,907 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 1,221,179 | USD | |
| At 2017-06-30 | 965,764 | USD |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-12-31 | 23,392 | USD | 184 |
| 2016-07-01 to 2016-12-31 | 23,530 | USD | 184 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | 500,000 | USD | 92 |
| 2017-07-01 to 2017-12-31 | 500,000 | USD | 184 |
| 2016-10-01 to 2016-12-31 | 0 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 0 | USD | 184 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | 466,083 | USD | 92 |
| 2017-07-01 to 2017-12-31 | 432,834 | USD | 184 |
| 2016-10-01 to 2016-12-31 | -22,447 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -32,701 | USD | 184 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-12-31 | 442,308 | USD | 184 |
| 2016-07-01 to 2016-12-31 | -117,965 | USD | 184 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-12-31 | 149,476 | USD | 184 |
| 2016-07-01 to 2016-12-31 | 107,642 | USD | 184 |
Inspect the source
- Entity
- Escalon Medical Corp. / CIK 0000862668
- Captured
- SEC response SHA-256
1553c3790334a15d4c4528d0e1ce16eac37d12130ed9cd66f6b338c07ce2533d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000862668.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))